GLOW (Blend)

What Is GLOW? GHK-Cu, BPC-157 and TB-500

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

GLOW is a co-lyophilised research blend of three peptides in one vial: GHK-Cu at 402.92 Da, BPC-157 at 1419.5 Da and TB-500 (full-length thymosin beta-4) at 4,963 Da, totalling 70mg. The per-component split is not stated, which is the defining limitation of the format.

Key facts

Components
Three
GHK-Cu
402.92 Da, CID 71587328
BPC-157
1419.5 Da, CID 9941957
TB-500 (thymosin beta-4)
4,963 Da
Total mass
70 mg
Per-component split
Not stated
Form
Co-lyophilised, single vial
Authorisation
None (components are unlicensed)

What co-lyophilised means

The GLOW peptide blend is three peptides combined in solution and freeze-dried together: one cake in one vial rather than three separate products. Reconstituting it puts all three into solution simultaneously, in whatever ratio was set at manufacture.

The three components

GHK-Cu is a copper-complexed tripeptide at 402.92 Da, associated with collagen and matrix remodelling research. BPC-157 is a fifteen-residue peptide at 1419.5 Da with a large preclinical repair literature and a recruiting Phase 2 trial. TB-500 here is full-length thymosin beta-4, 43 residues at 4,963 Da. Each has its own category on this site. The KLOW stack combines these same three components with KPV at 80mg total.

Research material referenced

GLOW 70mg, third-party HPLC tested

Buy GLOW · £59.99

The figure that is missing

70mg is a total. How that divides between three components is not stated, and every calculation anyone would want to perform requires knowing. This is not a criticism of one product. It is inherent to the blend format, and stating it clearly is more useful than working around it.

Why the components were chosen together

All three appear in connective tissue and matrix research literatures. GHK-Cu in collagen and remodelling work, BPC-157 in repair models, TB-500 in cell migration studies. The rationale is overlap of research area rather than any demonstrated interaction between them.

What has not been demonstrated

That the three do anything together that they do not do separately. There is no published work on this specific combination. The literature exists for each component individually. A blend is a convenience of packaging, not a studied entity, and no synergy claim can be supported.

Regulatory position

None of the three components holds a marketing authorisation from the MHRA, EMA or FDA, and neither does the blend. It is supplied for laboratory research only, with no claim about skin, ageing or any condition in any person.

Frequently asked questions

What is in GLOW?

GHK-Cu at 402.92 Da, BPC-157 at 1419.5 Da and TB-500 (full-length thymosin beta-4) at 4,963 Da, co-lyophilised together, totalling 70mg.

How much of each component is there?

The split is not stated. That is the defining limitation of a blend format, and it affects every calculation.

Is there research on the combination?

No. The literature exists for each component separately. No published work addresses this specific blend.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLOW (Blend) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.